Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

Summary

This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who have progressed after receiving at least one prior line of systemic therapy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.

Timeline

Start

2025-07-10

Primary completion

2027-07-10

Completion

2028-07-10

Drugs

Indications